viewFSD Pharma

Buds & Duds: Cannabis stocks close up on Monday; FSD Pharma shares soar on licensing milestone

Also on the move were The Green Organic Dutchman, Cannabis One, CannTrust and MariMed

FSD pharma facility
FSD Pharma plans to ramp-up production at its current facility located in Cobourg, Ontario

Cannabis stocks started the week with a bang, after a busy 4/20 weekend.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was up 2.5% to 301.34 by Monday's close. The Horizons Marijuana Life Sciences Index ETF was up 3.7% at C$20.92.


FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) announced Monday that it had hit a key milestone after its subsidary FV Pharma received its sales license to supply and sell cannabis products. The license, granted by Health Canada, went into effect on April 18, 2019.

Shares of FSD soared, up 24.4% at C$0.28 in Toronto, up 21.5% at US$0.21 in New York. 

READ: FSD Pharma granted cannabis sales license from Health Canada

The Toronto-based company plans to ramp up production at its current facility in Cobourg, Ontario while continuing to build out the plant to add additional grow capacity. 

The terms allow the current FSD facility to supply and sell cannabis products, while an amended sales license, expected in the near future, will include the sale of dried and fresh cannabis flower.

The sales license also allows FSD’s partner Canntab Therapeutics (CSE:PILL) to begin sales of its cannabis oral dose delivery platforms, including CBD and THC capsules, in Canada and internationally.

Shares of Canntab were also up on Monday, closing up 4% at C$0.78 in Toronto. 

“We expect that this will provide an immediate benefit to both parties, since FSD is entitled to a share of Canntab's revenue from sales as a result of the collaboration and profit sharing agreement that we entered into this past fall,” said FSD founder and president Zeeshan Saeed. 

READ: The Green Organic Dutchman receives Health Canada licence to sell cannabis oils

The Green Organic Dutchman Holdings Ltd (TSE:TGOD) (OTCMKTS:TGODF) shares jumped on Monday after it announced it has received its oil sales licence from Health Canada.

Shares of TGOD were up 6.9% at C$4.18 in Toronto and up 6.5% at US$3.13 in New York. 

"We are pleased to offer TGOD's medical patients access to new premium certified organic cannabis oils," said CEO Brian Athaide. "In addition, this step will assist TGOD in transforming our premium-quality organic raw material into a variety of higher-margin cannabis products which is core to our business plan, providing us with the opportunity to bring to market innovative and novel products, including beverages and edibles, once regulations permit. Cannabis 2.0 is rapidly approaching, and we will be ready."

READ: Cannabis One to acquire Nevada-based Evergreen Organix

Also on the rise Monday was Cannabis One Holdings Inc. (CSE:CBIS) (OTCMKTS:CAAOF), which announced a series of agreements to acquire Evergreen Organix, a Nevada-based cultivation, manufacturing and brand house.

Shares were up 3.7% at C$4.53 in Toronto, up 4.8% at US$3.41 in New York. 

The Denver-based company said in a statement that they had three definitive agreements to acquire certain assets of Nevada-based LV 3480 Partners LLC, 3480 Investors, Inc., and Agro Finance LLC, collectively known as Evergreen Organix.


A number of stocks lagged on Monday. 

MariMed Inc (OTCQB:MRMD) shares dropped on Monday, down 6.4% at US$3.27. Last week, the company reported its Q4 and annual 2018 fiscal results.

For the full year 2018, its revenues grew to US$11.85 million, up 95% over US$6.07 million reported for 2017. Its reported net loss for the year was US$13.6 million. 

Shares of MedMen Enterprises Inc (CSE:MMEN) (OTCQX:MMNFF) lagged on Monday, after it announced a number of top executives have resigned, including its general counsel and chief operating officer. The company also named Ryan Lissack as MedMen's new chief technology officer.

Shares were down 5.3% at US$2.86 in New York by Monday's close. 

Contact Katie Lewis at katie@proactiveinvestors.com

Quick facts: FSD Pharma

Price: 3.68 CAD

Market: CSE
Market Cap: $54.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...


FSD Pharma aims to initiate a Phase 2 coronavirus treatment trial by end...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) CEO Raza Bokhari tells Proactive the group has submitted an Investigational New Drug (IND) application to the FDA for the use of its lead candidate FSD-201, or anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA), to treat...

2 weeks, 5 days ago

4 min read